KalVista Pharmaceuticals (KALV) Cash & Equivalents (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Cash & Equivalents data on file, last reported at $124.3 million in Q3 2025.

• For the quarter ending Q3 2025, Cash & Equivalents rose 290.3% year-over-year to $124.3 million; the trailing twelve-month figure through Jul 2025 stood at $124.3 million (up 290.3% YoY), and the FY2025 full-year result was $131.6 million, up 314.03% from the prior year.
• Cash & Equivalents retreated to $124.3 million in Q3 2025, from $131.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $182.3 million in Q4 2024 to a low of $17.7 million in Q1 2021.
• A 5-year average of $59.5 million and a median of $46.5 million in 2021 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 72.89% in 2024 and jumped 314.03% in 2025, its largest moves.
• Tracing KALV's Cash & Equivalents over 5 years: stood at $46.5 million in 2021, then retreated by 17.01% to $38.6 million in 2022, then surged by 49.45% to $57.7 million in 2023, then jumped by 216.18% to $182.3 million in 2024, then slumped by 31.82% to $124.3 million in 2025.
• Business Quant data shows KALV's Cash & Equivalents at $124.3 million in Q3 2025, $131.6 million in Q2 2025, and $182.3 million in Q4 2024.